img

Global Anti-Viral Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Anti-Viral Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Antiviral drugs are a class of medication used specifically for treating viral infections rather than bacterial ones
The global Anti-Viral Drugs market size was US$ 117610 million in 2022 and is forecast to a readjusted size of US$ 150280 million by 2034 with a CAGR of 3.5% during the forecast period 2024-2034.
The United States market for Anti-Viral Drugs is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Anti-Viral Drugs is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Anti-Viral Drugs is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Anti-Viral Drugs include F. Hoffmann-La Roche, GlaxoSmithKline, Bristol-Myers-Squibb, AbbVie, Johnson & Johnson, Merck & Co, Aurobindo Pharma, Cipla and Dr Reddy’s, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Anti-Viral Drugs, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Anti-Viral Drugs by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Anti-Viral Drugs market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Anti-Viral Drugs market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


F. Hoffmann-La Roche
GlaxoSmithKline
Bristol-Myers-Squibb
AbbVie
Johnson & Johnson
Merck & Co
Aurobindo Pharma
Cipla
Dr Reddy’s
By Type
Nucleotide Polymerase Inhibitor
Reverse Transcriptase Inhibitor
Protease Inhibitor
By Application
HIV
Hepatitis
HSV
Influenza
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Anti-Viral Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Anti-Viral Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Viral Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Anti-Viral Drugs Definition
1.2 Market by Type
1.2.1 Global Anti-Viral Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Nucleotide Polymerase Inhibitor
1.2.3 Reverse Transcriptase Inhibitor
1.2.4 Protease Inhibitor
1.3 Market Segment by Application
1.3.1 Global Anti-Viral Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 HIV
1.3.3 Hepatitis
1.3.4 HSV
1.3.5 Influenza
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Anti-Viral Drugs Sales
2.1 Global Anti-Viral Drugs Revenue Estimates and Forecasts 2018-2034
2.2 Global Anti-Viral Drugs Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Anti-Viral Drugs Revenue by Region
2.3.1 Global Anti-Viral Drugs Revenue by Region (2018-2024)
2.3.2 Global Anti-Viral Drugs Revenue by Region (2024-2034)
2.4 Global Anti-Viral Drugs Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Anti-Viral Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Anti-Viral Drugs Sales Quantity by Region
2.6.1 Global Anti-Viral Drugs Sales Quantity by Region (2018-2024)
2.6.2 Global Anti-Viral Drugs Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Anti-Viral Drugs Sales Quantity by Manufacturers
3.1.1 Global Anti-Viral Drugs Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Anti-Viral Drugs Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Anti-Viral Drugs Sales in 2022
3.2 Global Anti-Viral Drugs Revenue by Manufacturers
3.2.1 Global Anti-Viral Drugs Revenue by Manufacturers (2018-2024)
3.2.2 Global Anti-Viral Drugs Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Anti-Viral Drugs Revenue in 2022
3.3 Global Anti-Viral Drugs Sales Price by Manufacturers
3.4 Global Key Players of Anti-Viral Drugs, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Anti-Viral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Anti-Viral Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Anti-Viral Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Anti-Viral Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Anti-Viral Drugs Sales Quantity by Type
4.1.1 Global Anti-Viral Drugs Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Anti-Viral Drugs Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Anti-Viral Drugs Sales Quantity Market Share by Type (2018-2034)
4.2 Global Anti-Viral Drugs Revenue by Type
4.2.1 Global Anti-Viral Drugs Historical Revenue by Type (2018-2024)
4.2.2 Global Anti-Viral Drugs Forecasted Revenue by Type (2024-2034)
4.2.3 Global Anti-Viral Drugs Revenue Market Share by Type (2018-2034)
4.3 Global Anti-Viral Drugs Price by Type
4.3.1 Global Anti-Viral Drugs Price by Type (2018-2024)
4.3.2 Global Anti-Viral Drugs Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Anti-Viral Drugs Sales Quantity by Application
5.1.1 Global Anti-Viral Drugs Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Anti-Viral Drugs Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Anti-Viral Drugs Sales Quantity Market Share by Application (2018-2034)
5.2 Global Anti-Viral Drugs Revenue by Application
5.2.1 Global Anti-Viral Drugs Historical Revenue by Application (2018-2024)
5.2.2 Global Anti-Viral Drugs Forecasted Revenue by Application (2024-2034)
5.2.3 Global Anti-Viral Drugs Revenue Market Share by Application (2018-2034)
5.3 Global Anti-Viral Drugs Price by Application
5.3.1 Global Anti-Viral Drugs Price by Application (2018-2024)
5.3.2 Global Anti-Viral Drugs Price Forecast by Application (2024-2034)
6 North America
6.1 North America Anti-Viral Drugs Sales by Company
6.1.1 North America Anti-Viral Drugs Revenue by Company (2018-2024)
6.1.2 North America Anti-Viral Drugs Sales Quantity by Company (2018-2024)
6.2 North America Anti-Viral Drugs Market Size by Type
6.2.1 North America Anti-Viral Drugs Sales Quantity by Type (2018-2034)
6.2.2 North America Anti-Viral Drugs Revenue by Type (2018-2034)
6.3 North America Anti-Viral Drugs Market Size by Application
6.3.1 North America Anti-Viral Drugs Sales Quantity by Application (2018-2034)
6.3.2 North America Anti-Viral Drugs Revenue by Application (2018-2034)
6.4 North America Anti-Viral Drugs Market Size by Country
6.4.1 North America Anti-Viral Drugs Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Anti-Viral Drugs Revenue by Country (2018-2034)
6.4.3 North America Anti-Viral Drugs Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Anti-Viral Drugs Sales by Company
7.1.1 Europe Anti-Viral Drugs Sales Quantity by Company (2018-2024)
7.1.2 Europe Anti-Viral Drugs Revenue by Company (2018-2024)
7.2 Europe Anti-Viral Drugs Market Size by Type
7.2.1 Europe Anti-Viral Drugs Sales Quantity by Type (2018-2034)
7.2.2 Europe Anti-Viral Drugs Revenue by Type (2018-2034)
7.3 Europe Anti-Viral Drugs Market Size by Application
7.3.1 Europe Anti-Viral Drugs Sales Quantity by Application (2018-2034)
7.3.2 Europe Anti-Viral Drugs Revenue by Application (2018-2034)
7.4 Europe Anti-Viral Drugs Market Size by Country
7.4.1 Europe Anti-Viral Drugs Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Anti-Viral Drugs Revenue by Country (2018-2034)
7.4.3 Europe Anti-Viral Drugs Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Anti-Viral Drugs Sales by Company
8.1.1 China Anti-Viral Drugs Sales Quantity by Company (2018-2024)
8.1.2 China Anti-Viral Drugs Revenue by Company (2018-2024)
8.2 China Anti-Viral Drugs Market Size by Type
8.2.1 China Anti-Viral Drugs Sales Quantity by Type (2018-2034)
8.2.2 China Anti-Viral Drugs Revenue by Type (2018-2034)
8.3 China Anti-Viral Drugs Market Size by Application
8.3.1 China Anti-Viral Drugs Sales Quantity by Application (2018-2034)
8.3.2 China Anti-Viral Drugs Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Anti-Viral Drugs Sales by Company
9.1.1 APAC Anti-Viral Drugs Sales Quantity by Company (2018-2024)
9.1.2 APAC Anti-Viral Drugs Revenue by Company (2018-2024)
9.2 APAC Anti-Viral Drugs Market Size by Type
9.2.1 APAC Anti-Viral Drugs Sales Quantity by Type (2018-2034)
9.2.2 APAC Anti-Viral Drugs Revenue by Type (2018-2034)
9.3 APAC Anti-Viral Drugs Market Size by Application
9.3.1 APAC Anti-Viral Drugs Sales Quantity by Application (2018-2034)
9.3.2 APAC Anti-Viral Drugs Revenue by Application (2018-2034)
9.4 APAC Anti-Viral Drugs Market Size by Region
9.4.1 APAC Anti-Viral Drugs Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Anti-Viral Drugs Revenue by Region (2018-2034)
9.4.3 APAC Anti-Viral Drugs Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Anti-Viral Drugs Sales by Company
10.1.1 Middle East, Africa and Latin America Anti-Viral Drugs Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Anti-Viral Drugs Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Anti-Viral Drugs Market Size by Type
10.2.1 Middle East, Africa and Latin America Anti-Viral Drugs Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Anti-Viral Drugs Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Anti-Viral Drugs Market Size by Application
10.3.1 Middle East, Africa and Latin America Anti-Viral Drugs Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Anti-Viral Drugs Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Anti-Viral Drugs Market Size by Country
10.4.1 Middle East, Africa and Latin America Anti-Viral Drugs Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Anti-Viral Drugs Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Anti-Viral Drugs Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Company Information
11.1.2 F. Hoffmann-La Roche Overview
11.1.3 F. Hoffmann-La Roche Anti-Viral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 F. Hoffmann-La Roche Anti-Viral Drugs Products and Services
11.1.5 F. Hoffmann-La Roche Anti-Viral Drugs SWOT Analysis
11.1.6 F. Hoffmann-La Roche Recent Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Information
11.2.2 GlaxoSmithKline Overview
11.2.3 GlaxoSmithKline Anti-Viral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 GlaxoSmithKline Anti-Viral Drugs Products and Services
11.2.5 GlaxoSmithKline Anti-Viral Drugs SWOT Analysis
11.2.6 GlaxoSmithKline Recent Developments
11.3 Bristol-Myers-Squibb
11.3.1 Bristol-Myers-Squibb Company Information
11.3.2 Bristol-Myers-Squibb Overview
11.3.3 Bristol-Myers-Squibb Anti-Viral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Bristol-Myers-Squibb Anti-Viral Drugs Products and Services
11.3.5 Bristol-Myers-Squibb Anti-Viral Drugs SWOT Analysis
11.3.6 Bristol-Myers-Squibb Recent Developments
11.4 AbbVie
11.4.1 AbbVie Company Information
11.4.2 AbbVie Overview
11.4.3 AbbVie Anti-Viral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 AbbVie Anti-Viral Drugs Products and Services
11.4.5 AbbVie Anti-Viral Drugs SWOT Analysis
11.4.6 AbbVie Recent Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Information
11.5.2 Johnson & Johnson Overview
11.5.3 Johnson & Johnson Anti-Viral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Johnson & Johnson Anti-Viral Drugs Products and Services
11.5.5 Johnson & Johnson Anti-Viral Drugs SWOT Analysis
11.5.6 Johnson & Johnson Recent Developments
11.6 Merck & Co
11.6.1 Merck & Co Company Information
11.6.2 Merck & Co Overview
11.6.3 Merck & Co Anti-Viral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Merck & Co Anti-Viral Drugs Products and Services
11.6.5 Merck & Co Anti-Viral Drugs SWOT Analysis
11.6.6 Merck & Co Recent Developments
11.7 Aurobindo Pharma
11.7.1 Aurobindo Pharma Company Information
11.7.2 Aurobindo Pharma Overview
11.7.3 Aurobindo Pharma Anti-Viral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Aurobindo Pharma Anti-Viral Drugs Products and Services
11.7.5 Aurobindo Pharma Anti-Viral Drugs SWOT Analysis
11.7.6 Aurobindo Pharma Recent Developments
11.8 Cipla
11.8.1 Cipla Company Information
11.8.2 Cipla Overview
11.8.3 Cipla Anti-Viral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Cipla Anti-Viral Drugs Products and Services
11.8.5 Cipla Anti-Viral Drugs SWOT Analysis
11.8.6 Cipla Recent Developments
11.9 Dr Reddy’s
11.9.1 Dr Reddy’s Company Information
11.9.2 Dr Reddy’s Overview
11.9.3 Dr Reddy’s Anti-Viral Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 Dr Reddy’s Anti-Viral Drugs Products and Services
11.9.5 Dr Reddy’s Anti-Viral Drugs SWOT Analysis
11.9.6 Dr Reddy’s Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Anti-Viral Drugs Value Chain Analysis
12.2 Anti-Viral Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anti-Viral Drugs Production Mode & Process
12.4 Anti-Viral Drugs Sales and Marketing
12.4.1 Anti-Viral Drugs Sales Channels
12.4.2 Anti-Viral Drugs Distributors
12.5 Anti-Viral Drugs Customers
13 Market Dynamics
13.1 Anti-Viral Drugs Industry Trends
13.2 Anti-Viral Drugs Market Drivers
13.3 Anti-Viral Drugs Market Challenges
13.4 Anti-Viral Drugs Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Anti-Viral Drugs Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Nucleotide Polymerase Inhibitor
Table 3. Major Manufacturers of Reverse Transcriptase Inhibitor
Table 4. Major Manufacturers of Protease Inhibitor
Table 5. Global Anti-Viral Drugs Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Anti-Viral Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Anti-Viral Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Anti-Viral Drugs Revenue Market Share by Region (2018-2024)
Table 9. Global Anti-Viral Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Anti-Viral Drugs Revenue Market Share by Region (2024-2034)
Table 11. Global Anti-Viral Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 12. Global Anti-Viral Drugs Sales by Region (2018-2024) & (K Units)
Table 13. Global Anti-Viral Drugs Sales Market Share by Region (2018-2024)
Table 14. Global Anti-Viral Drugs Sales by Region (2024-2034) & (K Units)
Table 15. Global Anti-Viral Drugs Sales Market Share by Region (2024-2034)
Table 16. Global Anti-Viral Drugs Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 17. Global Anti-Viral Drugs Sales Quantity Share by Manufacturers (2018-2024)
Table 18. Global Anti-Viral Drugs Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Anti-Viral Drugs Revenue Share by Manufacturers (2018-2024)
Table 20. Global Anti-Viral Drugs Price by Manufacturers 2018-2024 (USD/Unit)
Table 21. Global Key Players of Anti-Viral Drugs, Industry Ranking, 2021 VS 2022
Table 22. Global Anti-Viral Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Anti-Viral Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Viral Drugs as of 2022)
Table 24. Global Key Manufacturers of Anti-Viral Drugs, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Anti-Viral Drugs, Product Offered and Application
Table 26. Global Key Manufacturers of Anti-Viral Drugs, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Anti-Viral Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 29. Global Anti-Viral Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 30. Global Anti-Viral Drugs Sales Quantity Share by Type (2018-2024)
Table 31. Global Anti-Viral Drugs Sales Quantity Share by Type (2024-2034)
Table 32. Global Anti-Viral Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Anti-Viral Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Anti-Viral Drugs Revenue Share by Type (2018-2024)
Table 35. Global Anti-Viral Drugs Revenue Share by Type (2024-2034)
Table 36. Anti-Viral Drugs Price by Type (2018-2024) & (USD/Unit)
Table 37. Global Anti-Viral Drugs Price Forecast by Type (2024-2034) & (USD/Unit)
Table 38. Global Anti-Viral Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 39. Global Anti-Viral Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 40. Global Anti-Viral Drugs Sales Quantity Share by Application (2018-2024)
Table 41. Global Anti-Viral Drugs Sales Quantity Share by Application (2024-2034)
Table 42. Global Anti-Viral Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Anti-Viral Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Anti-Viral Drugs Revenue Share by Application (2018-2024)
Table 45. Global Anti-Viral Drugs Revenue Share by Application (2024-2034)
Table 46. Anti-Viral Drugs Price by Application (2018-2024) & (USD/Unit)
Table 47. Global Anti-Viral Drugs Price Forecast by Application (2024-2034) & (USD/Unit)
Table 48. North America Anti-Viral Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 49. North America Anti-Viral Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 50. North America Anti-Viral Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 51. North America Anti-Viral Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 52. North America Anti-Viral Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 53. North America Anti-Viral Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Anti-Viral Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 55. North America Anti-Viral Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 56. North America Anti-Viral Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 57. North America Anti-Viral Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Anti-Viral Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 59. North America Anti-Viral Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 60. North America Anti-Viral Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Anti-Viral Drugs Sales Quantity by Country (2018-2024) & (K Units)
Table 62. North America Anti-Viral Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 63. Europe Anti-Viral Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 64. Europe Anti-Viral Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 65. Europe Anti-Viral Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 66. Europe Anti-Viral Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 67. Europe Anti-Viral Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 68. Europe Anti-Viral Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Anti-Viral Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 70. Europe Anti-Viral Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 71. Europe Anti-Viral Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 72. Europe Anti-Viral Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Anti-Viral Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 74. Europe Anti-Viral Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 75. Europe Anti-Viral Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Anti-Viral Drugs Sales Quantity by Country (2018-2024) & (K Units)
Table 77. Europe Anti-Viral Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 78. China Anti-Viral Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 79. China Anti-Viral Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 80. China Anti-Viral Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 81. China Anti-Viral Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 82. China Anti-Viral Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 83. China Anti-Viral Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Anti-Viral Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 85. China Anti-Viral Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 86. China Anti-Viral Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 87. China Anti-Viral Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Anti-Viral Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 89. APAC Anti-Viral Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 90. APAC Anti-Viral Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 91. APAC Anti-Viral Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 92. APAC Anti-Viral Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 93. APAC Anti-Viral Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Anti-Viral Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 95. APAC Anti-Viral Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 96. APAC Anti-Viral Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 97. APAC Anti-Viral Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Anti-Viral Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 99. APAC Anti-Viral Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 100. APAC Anti-Viral Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Anti-Viral Drugs Sales Quantity by Region (2018-2024) & (K Units)
Table 102. APAC Anti-Viral Drugs Sales Quantity by Region (2024-2034) & (K Units)
Table 103. Middle East, Africa and Latin America Anti-Viral Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 104. Middle East, Africa and Latin America Anti-Viral Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Anti-Viral Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Anti-Viral Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 107. Middle East, Africa and Latin America Anti-Viral Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 108. Middle East, Africa and Latin America Anti-Viral Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Anti-Viral Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 110. Middle East, Africa and Latin America Anti-Viral Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 111. Middle East, Africa and Latin America Anti-Viral Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 112. Middle East, Africa and Latin America Anti-Viral Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Anti-Viral Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Anti-Viral Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 115. Middle East, Africa and Latin America Anti-Viral Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Anti-Viral Drugs Sales Quantity by Country (2018-2024) & (K Units)
Table 117. Middle East, Africa and Latin America Anti-Viral Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 118. F. Hoffmann-La Roche Company Information
Table 119. F. Hoffmann-La Roche Description and Overview
Table 120. F. Hoffmann-La Roche Anti-Viral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 121. F. Hoffmann-La Roche Anti-Viral Drugs Product and Services
Table 122. F. Hoffmann-La Roche Anti-Viral Drugs SWOT Analysis
Table 123. F. Hoffmann-La Roche Recent Developments
Table 124. GlaxoSmithKline Company Information
Table 125. GlaxoSmithKline Description and Overview
Table 126. GlaxoSmithKline Anti-Viral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 127. GlaxoSmithKline Anti-Viral Drugs Product and Services
Table 128. GlaxoSmithKline Anti-Viral Drugs SWOT Analysis
Table 129. GlaxoSmithKline Recent Developments
Table 130. Bristol-Myers-Squibb Company Information
Table 131. Bristol-Myers-Squibb Description and Overview
Table 132. Bristol-Myers-Squibb Anti-Viral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 133. Bristol-Myers-Squibb Anti-Viral Drugs Product and Services
Table 134. Bristol-Myers-Squibb Anti-Viral Drugs SWOT Analysis
Table 135. Bristol-Myers-Squibb Recent Developments
Table 136. AbbVie Company Information
Table 137. AbbVie Description and Overview
Table 138. AbbVie Anti-Viral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 139. AbbVie Anti-Viral Drugs Product and Services
Table 140. AbbVie Anti-Viral Drugs SWOT Analysis
Table 141. AbbVie Recent Developments
Table 142. Johnson & Johnson Company Information
Table 143. Johnson & Johnson Description and Overview
Table 144. Johnson & Johnson Anti-Viral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 145. Johnson & Johnson Anti-Viral Drugs Product and Services
Table 146. Johnson & Johnson Anti-Viral Drugs SWOT Analysis
Table 147. Johnson & Johnson Recent Developments
Table 148. Merck & Co Company Information
Table 149. Merck & Co Description and Overview
Table 150. Merck & Co Anti-Viral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 151. Merck & Co Anti-Viral Drugs Product and Services
Table 152. Merck & Co Anti-Viral Drugs SWOT Analysis
Table 153. Merck & Co Recent Developments
Table 154. Aurobindo Pharma Company Information
Table 155. Aurobindo Pharma Description and Overview
Table 156. Aurobindo Pharma Anti-Viral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 157. Aurobindo Pharma Anti-Viral Drugs Product and Services
Table 158. Aurobindo Pharma Anti-Viral Drugs SWOT Analysis
Table 159. Aurobindo Pharma Recent Developments
Table 160. Cipla Company Information
Table 161. Cipla Description and Overview
Table 162. Cipla Anti-Viral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 163. Cipla Anti-Viral Drugs Product and Services
Table 164. Cipla Anti-Viral Drugs SWOT Analysis
Table 165. Cipla Recent Developments
Table 166. Dr Reddy’s Company Information
Table 167. Dr Reddy’s Description and Overview
Table 168. Dr Reddy’s Anti-Viral Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 169. Dr Reddy’s Anti-Viral Drugs Product and Services
Table 170. Dr Reddy’s Anti-Viral Drugs SWOT Analysis
Table 171. Dr Reddy’s Recent Developments
Table 172. Key Raw Materials Lists
Table 173. Raw Materials Key Suppliers Lists
Table 174. Anti-Viral Drugs Distributors List
Table 175. Anti-Viral Drugs Customers List
Table 176. Anti-Viral Drugs Market Trends
Table 177. Anti-Viral Drugs Market Drivers
Table 178. Anti-Viral Drugs Market Challenges
Table 179. Anti-Viral Drugs Market Restraints
Table 180. Research Programs/Design for This Report
Table 181. Key Data Information from Secondary Sources
Table 182. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Viral Drugs Product Picture
Figure 2. Global Anti-Viral Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Anti-Viral Drugs Market Share by Type in 2022 & 2034
Figure 4. Nucleotide Polymerase Inhibitor Product Picture
Figure 5. Reverse Transcriptase Inhibitor Product Picture
Figure 6. Protease Inhibitor Product Picture
Figure 7. Global Anti-Viral Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 8. Global Anti-Viral Drugs Market Share by Application in 2022 & 2034
Figure 9. HIV
Figure 10. Hepatitis
Figure 11. HSV
Figure 12. Influenza
Figure 13. Anti-Viral Drugs Report Years Considered
Figure 14. Global Anti-Viral Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Anti-Viral Drugs Revenue 2018-2034 (US$ Million)
Figure 16. Global Anti-Viral Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 17. Global Anti-Viral Drugs Sales Quantity 2018-2034 (K Units)
Figure 18. Global Anti-Viral Drugs Sales Quantity Market Share by Region (2018-2024)
Figure 19. Global Anti-Viral Drugs Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Anti-Viral Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. North America Anti-Viral Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Anti-Viral Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. Europe Anti-Viral Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Anti-Viral Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. China Anti-Viral Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Anti-Viral Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. APAC Anti-Viral Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Anti-Viral Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 29. Middle East, Africa and Latin America Anti-Viral Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Anti-Viral Drugs Sales Quantity in 2022
Figure 31. The Top 10 and Top 5 Players Market Share by Anti-Viral Drugs Revenue in 2022
Figure 32. Anti-Viral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Anti-Viral Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Anti-Viral Drugs Revenue Market Share by Type (2018-2034)
Figure 35. Global Anti-Viral Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Anti-Viral Drugs Revenue Market Share by Application (2018-2034)
Figure 37. North America Anti-Viral Drugs Revenue Market Share by Company in 2022
Figure 38. North America Anti-Viral Drugs Sales Quantity Market Share by Company in 2022
Figure 39. North America Anti-Viral Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Anti-Viral Drugs Revenue Market Share by Type (2018-2034)
Figure 41. North America Anti-Viral Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Anti-Viral Drugs Revenue Market Share by Application (2018-2034)
Figure 43. North America Anti-Viral Drugs Revenue Share by Country (2018-2034)
Figure 44. North America Anti-Viral Drugs Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Anti-Viral Drugs Sales Quantity Market Share by Company in 2022
Figure 48. Europe Anti-Viral Drugs Revenue Market Share by Company in 2022
Figure 49. Europe Anti-Viral Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Anti-Viral Drugs Revenue Market Share by Type (2018-2034)
Figure 51. Europe Anti-Viral Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Anti-Viral Drugs Revenue Market Share by Application (2018-2034)
Figure 53. Europe Anti-Viral Drugs Revenue Share by Country (2018-2034)
Figure 54. Europe Anti-Viral Drugs Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 56. France Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 60. China Anti-Viral Drugs Sales Quantity Market Share by Company in 2022
Figure 61. China Anti-Viral Drugs Revenue Market Share by Company in 2022
Figure 62. China Anti-Viral Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Anti-Viral Drugs Revenue Market Share by Type (2018-2034)
Figure 64. China Anti-Viral Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Anti-Viral Drugs Revenue Market Share by Application (2018-2034)
Figure 66. APAC Anti-Viral Drugs Sales Quantity Market Share by Company in 2022
Figure 67. APAC Anti-Viral Drugs Revenue Market Share by Company in 2022
Figure 68. APAC Anti-Viral Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Anti-Viral Drugs Revenue Market Share by Type (2018-2034)
Figure 70. APAC Anti-Viral Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Anti-Viral Drugs Revenue Market Share by Application (2018-2034)
Figure 72. APAC Anti-Viral Drugs Revenue Share by Region (2018-2034)
Figure 73. APAC Anti-Viral Drugs Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 78. India Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Anti-Viral Drugs Sales Quantity Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Anti-Viral Drugs Revenue Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Anti-Viral Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Anti-Viral Drugs Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Anti-Viral Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Anti-Viral Drugs Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Anti-Viral Drugs Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Anti-Viral Drugs Revenue Share by Country (2018-2034)
Figure 87. Brazil Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Anti-Viral Drugs Revenue (2018-2034) & (US$ Million)
Figure 92. Anti-Viral Drugs Value Chain
Figure 93. Anti-Viral Drugs Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed